Korro Bio (KRRO) Capital Expenditures (2018 - 2026)
Korro Bio's (KRRO) quarterly Capital Expenditures came in at $21000.0 in Q1 2026, down 82.35% YoY from $119000.0 in Q1 2025, and down 75.0% on a QoQ basis from $84000.0 in Q4 2025.
Korro Bio (KRRO) Capital Expenditures (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Capital Expenditures data on file, last reported at $21000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 82.35% year-over-year to $21000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $420000.0 (down 96.62% YoY) and the FY2025 annual result came in at $518000.0, down 97.11% from the prior year.
- Capital Expenditures fell to $21000.0 in Q1 2026, from $84000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $6.0 million in Q2 2024 to a low of -$16000.0 in Q3 2022.
- A 5-year average of $1.8 million and a median of $246000.0 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures sank 100.76% — and 2023, when it surged 110450.0%.
- Tracing KRRO's Capital Expenditures over 5 years: stood at $5.1 million in 2022, then sank by 67.78% to $1.7 million in 2023, then slipped by 12.27% to $1.5 million in 2024, then slumped by 94.21% to $84000.0 in 2025, then slumped by 75.0% to $21000.0 in 2026.
- The last three Capital Expenditures figures came in at $21000.0 (Q1 2026), $84000.0 (Q4 2025), and $175000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | 37,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37,000.00 |
| Jun 30, 2026 | 37,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Sep 30, 2025 | 175,000.00 |
| Sep 30, 2025 | 175,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Dec 31, 2024 | 1.45 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Jun 30, 2024 | 5.96 Mn |
| Jun 30, 2024 | 5.96 Mn |
| Mar 31, 2024 | 5.61 Mn |
| Mar 31, 2024 | 5.61 Mn |